Author:
Zheng Xiaoqin,Jin Wenjie,Wang Shanshan,Ding Huiguo
Abstract
Primary liver cancer (PLC) is one of the most common malignancies in China, where it ranks second in mortality and fifth in morbidity. Currently, liver transplantation, hepatic tumor resection, radiofrequency ablation, and molecular-targeted agents are the major treatments for hepatocellular carcinoma (HCC). Overall, HCC has a poor survival rate and a high recurrence rate. Tumor-infiltrating lymphocytes (TILs) have been discovered to play essential roles in the development, prognosis, and immunotherapy treatment of HCC. As the major component cells of TILs, T cells are also proved to show antitumor and protumor effects in HCC. Foxp3+, CD8+, CD3+, and CD4+ T lymphocytes are the broadly studied subgroups of TILs. This article reviews the roles and mechanisms of different tumor-infiltrating T lymphocyte subtypes in HCC.
Subject
Immunology,Immunology and Allergy
Reference115 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA: Cancer J Clin,2021
2. Cancer Incidence and Mortality in China, 2015;Zhang;J Natl Cancer Center,2021
3. EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma;J Hepatol,2018
4. A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management;Yang;Nat Rev Gastroenterol Hepatol,2019
5. Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis;Tabrizian;Ann Surg,2015
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献